MRD negativity: considerations for older adults with multiple myeloma
Blood Cancer J
.
2023 Nov 8;13(1):166.
doi: 10.1038/s41408-023-00939-y.
Authors
Hira Mian
1
,
Tanya M Wildes
2
,
Christopher P Venner
3
,
Rafael Fonseca
4
Affiliations
1
Department of Oncology, McMaster University, Hamilton, ON, Canada. hira.mian@medportal.ca.
2
Department of Hematology/Oncology, University of Nebraska Medical Center/Nebraska Medicine, Omaha, NE, USA.
3
Department of Medical Oncology, Centre for Lymphoid Cancers, University of British Columbia, Vancouver, BC, Canada.
4
Division of Hematology and Medical Oncology, Mayo Clinic in Arizona, Phoenix, AZ, USA.
PMID:
37938551
PMCID:
PMC10632351
DOI:
10.1038/s41408-023-00939-y
No abstract available
Publication types
Editorial
Research Support, Non-U.S. Gov't
MeSH terms
Aged
Humans
Multiple Myeloma* / diagnosis
Multiple Myeloma* / therapy